Your trusted destination for CME, CPD & Medical Education across the Middle East.
Princess Noorah Oncology Center, National Guard Health Affairs
Dr. Meteb H. Al-Foheidi is a Saudi-based consultant medical oncologist specializing in breast cancer, with extensive clinical, academic, and research experience in the management of breast malignancies. His professional work focuses on advancing breast cancer care through evidence-based treatment, clinical research, and the development of multidisciplinary approaches to cancer management. He holds the qualifications of Doctor of Medicine (MD) and Fellow of the Royal College of Physicians of Canada (FRCPC).
Dr. Al-Foheidi graduated with a Bachelor of Medicine and Bachelor of Surgery (MBBS) degree from King Faisal University in Dammam, Saudi Arabia, in January 2000. He subsequently pursued postgraduate medical training in Canada, completing his Internal Medicine residency at the University of Toronto between 2004 and 2007. He continued his specialist training in Medical Oncology at the University of British Columbia from 2007 to 2009, followed by an additional fellowship in breast cancer at the British Columbia Cancer Agency in Vancouver from 2009 to 2010.
Following his specialist training, Dr. Al-Foheidi established his clinical and academic career in Saudi Arabia. He has been associated with the Princess Noorah Oncology Center at King Abdulaziz Medical City in Jeddah, where he provides specialized oncology care. He also serves as an Assistant Professor at King Saud bin Abdulaziz University for Health Sciences, contributing to medical education and the development of future healthcare professionals. His academic responsibilities have included coordinating the Medical Oncology Block.
Dr. Al-Foheidi's clinical interests include early-stage and advanced breast cancer, hormone receptor-positive disease, HER2-positive breast cancer, and the use of targeted and endocrine therapies. His research has addressed breast cancer treatment outcomes, chemotherapy selection, molecular biomarkers, biosimilar medicines, and the management of treatment-related complications. He has contributed to numerous scientific publications and collaborative studies examining cancer treatment practices and outcomes in Saudi Arabia.

LUMINA
LUMINA